Earlier in January, the company received the Establishment Inspection Report (EIR) from USFDA for its Pithampur Unit-1 ...

A meeting of the board of directors of the company is scheduled to be held on February 11, 2025, to consider and approve the ...

Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...

Lupin receives US FDA approval for generic Atrovent nasal spray, 0.06%: Our Bureau,Mumbai Tuesday, January 28, 2025, 17:30 Hrs [IST] Global pharma major Lupin Limited (Lupin) anno ...

Lupin is an innovation led Transnational Pharmaceutical Company producing developing and ... Lupin Receives EIR from U. S. FDA for its Pithampur Unit-1 Facility with VAI Classification.

Lupin has obtained approval from the USFDA to market a generic form of an HIV medication. The approved drug, equivalent to Symtuza tablets, positions Lupin as the exclusive first-to-file. The tablets ...

Considering today's low, the Nifty pharma index has fallen over 7 per cent in the last three days. On a monthly scale, the index has declined nearly 12 per cent against a 3 per cent fall in the ...

Finance Minister Sitharaman announced the inclusion of six life-saving drugs in the concessional 5% duty slab to enhance ...

The Nifty Pharma index fell nearly 3% in intraday trade on January 28, marking its third consecutive session of decline, with Granules India, Biocon, Sun Pharma, and Lupin being the biggest losers.